Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

This study aimed to construct a physiologically based pharmacokinetic (PBPK) model of rifampicin that can accurately and quantitatively predict complex drug‐drug interactions (DDIs) involving its saturable hepatic uptake and auto‐induction. Using in silico and in vitro parameters, and reported clinical pharmacokinetic data, rifampicin PBPK model was built and relevant parameters for saturable hepatic uptake and UDP‐glucuronosyltransferase (UGT) auto‐induction were optimized by fitting. The parameters for cytochrome P450 (CYP) 3A and CYP2C9 induction by rifampicin were similarly optimized using clinical DDI data with midazolam and tolbutamide as probe substrates, respectively. For validation, our current PBPK model was applied to simulate complex DDIs with glibenclamide (a substrate of CYP3A/2C9 and hepatic organic anion transporting polypeptides (OATPs)). Simulated results were in quite good accordance with the observed data. Altogether, our constructed PBPK model of rifampicin demonstrates the robustness and utility in quantitatively predicting CYP3A/2C9 induction‐mediated and/or OATP inhibition‐mediated DDIs with victim drugs.

[1]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[2]  Y. Sugiyama,et al.  Analysis of Nonlinear and Nonsteady State Hepatic Extraction with the Dispersion Model Using the Finite Difference Method , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  G. Acocella,et al.  Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. , 1971, Chemotherapy.

[4]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[5]  S. Haddad,et al.  Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies the Albumin-Facilitated Uptake Mechanism(s) in Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling Research. , 2015, Journal of pharmaceutical sciences.

[6]  W. Ambrosius,et al.  The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity , 2003, Clinical pharmacology and therapeutics.

[7]  Mikko Niemi,et al.  Pharmacokinetic Interactions with Rifampicin , 2003, Clinical pharmacokinetics.

[8]  K. Knights,et al.  The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9 , 2008, Drug Metabolism and Disposition.

[9]  G. Acocella,et al.  Kinetic Studies on Rifampicin , 1971 .

[10]  B. Tomlinson,et al.  CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects , 2005, Clinical pharmacology and therapeutics.

[11]  E. Kharasch,et al.  Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First‐Pass CYP3A Induction , 2011, Clinical pharmacology and therapeutics.

[12]  M. Jamei,et al.  Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model , 2016, Drug Metabolism and Disposition.

[13]  L. Benet,et al.  Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite , 2009, Clinical pharmacology and therapeutics.

[14]  Prajakti A Kothare,et al.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.

[15]  Jian Lin,et al.  Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide , 2014, The AAPS Journal.

[16]  R. Scotti,et al.  Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. , 1967, Arzneimittel-Forschung.

[17]  H K Kroemer,et al.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.

[18]  S. Sunahara,et al.  [Increased desacetylation of rifampicin and an adverse reaction (author's transl)]. , 1981, Kekkaku : [Tuberculosis].

[19]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[20]  B. Kaufmann,et al.  Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). , 1985, International journal of clinical pharmacology, therapy, and toxicology.

[21]  M. Hebert,et al.  Contributions of human cytochrome P450 enzymes to glyburide metabolism , 2010, Biopharmaceutics & drug disposition.

[22]  Yuichi Sugiyama,et al.  The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. , 2005, Drug metabolism and pharmacokinetics.

[23]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[25]  P. Neuvonen,et al.  Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. , 2007, British journal of clinical pharmacology.

[26]  G. Acocella.  Clinical Pharmacokinetics of Rifampicin , 1978, Clinical pharmacokinetics.

[27]  P. Neuvonen,et al.  Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes , 2002, Clinical pharmacology and therapeutics.

[28]  Kazuya Maeda,et al.  Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. , 2012, International journal of clinical pharmacology and therapeutics.

[29]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[30]  H. Glaeser,et al.  Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. , 2005, British journal of clinical pharmacology.

[31]  M. Eichelbaum,et al.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration , 1985, Klinische Wochenschrift.

[32]  R. Jelliffe,et al.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide , 1997, Antimicrobial agents and chemotherapy.

[33]  J. Stout,et al.  Pharmacokinetics of rifampicin. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  K. Pang,et al.  Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.

[35]  K. Maeda,et al.  Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method , 2016, Clinical pharmacology and therapeutics.

[36]  K. Maeda.  Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.

[37]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[38]  D. Breimer,et al.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance , 1975, European Journal of Clinical Pharmacology.

[39]  Kazuya Maeda,et al.  Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data , 2009, Pharmaceutical Research.

[40]  J. Fleishaker,et al.  Evaluation of a Potential Interaction Between Erythromycin and Glyburide in Diabetic Volunteers , 1991, Journal of clinical pharmacology.

[41]  G. Segre,et al.  Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week. , 1978, Pharmacological research communications.

[42]  G. Beastall,et al.  Effect of oral verapamil on glibenclamide stimulated insulin secretion. , 1986, British journal of clinical pharmacology.

[43]  K. Brøsen,et al.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.

[44]  D. Mattison,et al.  Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. , 2009, Biochemical pharmacology.

[45]  C. Schäfer,et al.  Clinical relevance. , 2010, Deutsches Arzteblatt international.

[46]  Wolfgang Rohde,et al.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[47]  G. Acocella,et al.  Serum and urine concentrations of rifampicin administered by intravenous infusion in man. , 1977, Arzneimittel-Forschung.